Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide

Journal of the American Society of Nephrology

Volumn 16, Issue 4, 2005, Pages 959-965

  Passauer, Jens ^a   Pistrosch, Frank ^a   Büssemaker, Eckhart ^a   Lässig, Grit ^a   Herbrig, Kay ^a   Gross, Peter ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARGININE DERIVATIVE; IBUPROFEN; N MONOMETHYL LEVO ARGININE; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; ENZYME INHIBITOR; VASODILATOR AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG INHIBITION; ENDOTHELIUM; FOREARM BLOOD FLOW; HEMODIALYSIS; HUMAN; INFUSION; MALE; PRIORITY JOURNAL; UREMIA; VASCULAR DISEASE; VASODILATATION; BLOOD FLOW; CASE CONTROL STUDY; DOSE RESPONSE; DRUG EFFECT; FOREARM; METABOLISM; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; VASCULARIZATION; VASOCONSTRICTION;

ACETYLCHOLINE; ADULT; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM; ENZYME INHIBITORS; EPOPROSTENOL; FOREARM; HUMANS; NITRIC OXIDE; NITROPRUSSIDE; NOREPINEPHRINE; OMEGA-N-METHYLARGININE; REGIONAL BLOOD FLOW; RENAL DIALYSIS; UREMIA; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 24344463489     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004070582     Document Type: Article

References (43)

1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9[Suppl]: S16-S23, 1998
2. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41: 718-724, 2003
3. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
4. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141, 1998
5. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17: 1684-1688, 2002
6. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W: Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290: 353-359, 2003
7. Busch M, Franke S, Muller A, Wolf M, Gerth J, Ott U, Niwa T, Stein G: Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 66: 338-347, 2004
8. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37: 45-53, 1996
9. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12: 2747-2752, 2001
10. Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figliuzzi M, Remuzzi G: Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 44: 445-450, 1993
11. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D, Remuzzi G: Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 52: 171-181, 1997
12. Lau T, Owen W, Yu YM, Noviski N, Lyons J, Zurakowski D, Tsay R, Ajami A, Young VR, Castillo L: Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest 105: 1217-1225, 2000
13. Matsumoto A, Hirata Y, Kakoki M, Nagata D, Momomura S, Sugimoto T, Tagawa H, Omata M: Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure. Clin Sci (Colch) 96: 67-74, 1999
14. Roccatello D, Mengozzi G, Alfieri V, Pignone E, Menegatti E, Cavalli G, Cesano G, Rossi D, Formica M, Inconis T, Martina G, Paradisi L, Sena LM, Piccoli G: Early increase in blood nitric oxide, detected by electron paramagnetic resonance as nitrosylhaemoglobin, in haemodialysis. Nephrol Dial Transplant 12: 292-297, 1997
15. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, Versluis K, Lagerwerf F, van Rijn H, Koomans H, Rabelink T: Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 19: 1168-1172, 1999
16. Schmidt RJ, Baylis C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58: 1261-1266, 2000
17. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M: Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 61: 586-590, 2002
18. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39:135-141, 2002
19. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH: EDHF: Bringing the concepts together. Trends Pharmacol Sci 23: 374-380, 2002
20. Kalliovalkama J, Jolma P, Tolvanen JP, Kahonen M, Hutri-Kahonen N, Saha H, Tuorila S, Moilanen E, Porsti I: Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. Am J Physiol 277[Suppl]: H1622-H1629, 1999
21. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104: 191-196, 2001
22. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation 106: 653-658, 2002
23. Passauer J, Bussemaker E, Range U, Plug M, Gross P: Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 11: 1726-1734, 2000
24. Dawes M, Chowienczyk PJ, Ritter JM: Quantitative aspects of the inhibition by N(G)-monomethyl-L-arginine of responses to endothelium-dependent vasodilators in human forearm vasculature. Br J Pharmacol 134: 939-944, 2001
25. Carlsson I, Wennmalm A: Effect of different prostaglandin synthesis inhibitors on post-occlusive blood flow in human forearm. Prostaglandins 26: 241-252, 1983
26. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D: Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25: 918-923, 1995
27. Petrie JR, Ueda S, Morris AD, Murray LS, Elliott HL, Connell JM: How reproducible is bilateral forearm plethysmography? Br J Clin Pharmacol 45:131-139, 1998
28. Stroes ES, Luscher TF, de Groot FG, Koomans HA, Rabelink TJ: Cyclosporin A increases nitric oxide activity in vivo. Hypertension 29: 570-575, 1997
29. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97: 752-756, 1998
30. Honing ML, Smits P, Morrison PJ, Rabelink TJ: Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension 35: 1314-1318, 2000
31. Honing ML, Smits P, Morrison PJ, Burnett JC Jr, Rabelink TJ: C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension 37: 1179-1183, 2001
32. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
33. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60: 1077-1082, 2001
34. Mendes Ribeiro AC, Brunini TM, Ellory JC, Mann GE: Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res 49: 697-712, 2001
35. Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H, Hosoya T: Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dial Transplant 17: 1032-1036, 2002
36. Ferraro B, Galli F, Frei B, Kingdon E, Canestrari F, Rice-Evans C, Buoncristiani U, Davenport A, Moore KP: Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Int 63: 2207-2213, 2003
37. Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, MacAllister RJ: Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 63: 1433-1442, 2003
38. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK: Oxidative stress and dysregulation of Superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63: 179-185, 2003
39. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS: Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 279: F671-F678, 2000
40. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15: 538-548, 2004
41. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R: Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94: 3341-3347, 1996
42. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A: Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 100: 1400-1405, 1999
43. Quilley J, Fulton D, McGiff JC: Hyperpolarizing factors. Biochem Pharmacol 54: 1059-1070, 1997